Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds. Rising interest rates, challenges in the U.S. healthcare system, and the ...
FDA approves first new non-opioid pain pill in 20 years—how it works
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
FOX 7 Austin KTBC11d
FDA approves first new non-opioid pain pill in 20 years—how it works
(Photo by Sarah Silbiger ... approved for acute pain relief, Vertex Pharmaceuticals is working on expanding its use for chronic pain. However, the company’s stock plummeted in December after ...
First New Non-Opioid Painkiller Approved In The US For Decades Here's How It Works
A new non-opioid painkiller, suzetrigine , has just been approved by the US drug regulator, the FDA. It is the first non-opioid painkiller the agency ...
The Motley Fool6d
Investing in Genomics Stocks
Image source: Getty Images. Exact Sciences (NASDAQ ... Fulgent Genetics, Ionis Pharmaceuticals, Vertex Pharmaceuticals, and Zillow Group. The Motley Fool recommends Biogen, Exact Sciences ...
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
This was the stock's second consecutive day of losses.
Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?
Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...